Antifungal activity of biosynthesized silver nanoparticles from Candida albicans on the strain lacking the CNP41 gene

The flowchart of the procedures has been presented in figure 1. Briefly, double copy deletion of CNP41 has been done in two phases, Phase I and Phase II. Biosynthesis of silver nanoparticles was followed by its primary and secondary detection and characterization. Lastly, these nanoparticles were tested on CNP41 deleted strain for their antifungal activity.

Zoom In Zoom Out Reset image size

Candida albicans strain C86 (Δura3::imm434/Δura3::imm434 Δleu2::FRT/Δleu2::FRT) was derived from CAF4-2 (Δura3::imm434/Δura3::imm434) [15] by deleting both the copies of LEU2 gene using construct pKA76 [16] and evicting URA3 flipper as described by Morschhäuser et al [17]. The plasmid pKA76 was digested with KpnI-SacI to release the deletion cassette and transformed into parental strain CAF4-2 to delete both the copies of LEU2 gene and URA3 flipper was evicted by incubating in yeast carbon base (YCB) media in presence of bovine serum albumin as described by Morschhäuser et al [17]. The resulting strain C86 was used for deleting the gene CNP41 (orf19.3120). For routine amplification of plasmids and subcloning of DNA fragments, Escherichia coli strain XL-1 Blue was used [18]. Table 1 details the strains used in this study.

Yeast extract/peptone/dextrose (YPD) and synthetic dextrose (SD) media were prepared for culturing the yeast strain as described [19]. Uridine 50 μg ml⁻¹ was supplemented additionally as per the requirement. Strains were maintained in 15% v/v glycerol stock and stored in −80 °C. Candida albicans strains were streaked freshly to avoid spontaneous chromosomal instability when required [20]. Bacterial strains were grown in yeast extract/tryptone/sodium chloride (YT) media (0.5% sodium chloride, 0.5% yeast extract and 1% tryptone) at 37 °C. Plasmids were amplified in YT media containing 100 μg ml⁻¹ of ampicillin.

PCR amplification was performed using a thermal cycler as described [21]. Restriction digestion of plasmids, gel elution of DNA fragments, ligation of DNA fragments into vectors were carried out as described [22]. Plasmids were isolated by alkaline lysis method [23]. E. coli transformation was carried out by calcium chloride method [24]. C. albicans transformation was done by spheroplast method [25, 26].

Plasmid pUC19 was used for cloning and sequencing purposes [27]. The plasmid pSFU1 containing URA3 flipper was provided by. Morschhäuser as a gift. The plasmid pKA16 was made by subcloning a 1.4 kb SalI-PstI fragment containing URA3 (digested out from pSFU1) into pUC19 at SalI/PstI site. The plasmid pKA16 was used as basic plasmid to make constructs for gene/ORF deletion. Primers used in this study are listed in table 2. Primers KC16, KC17 (URA3) and KC195, KC206 (LEU2) are made using internal sequences of selection markers [16].

The LEU2 deletion construct was made by subcloning flanking sequences of LEU2 gene into URA3 flipper plasmid pSFUI. Upstream and downstream sequences were amplified using the primers KC74/KC75 and KC76/KC77 from CAF4-2 genomic DNA. The PCR products were inserted into plasmid pSFUI at KpnI/XhoI and SacI/NotI sites generating pKA76. The plasmid pKA76 can be digested with KpnI-SacI to release the deletion cassette and transform into recipient Candida strain.

The CNP41 gene deletion was done as shown in figure 2. The CNP41 gene deletion construct was made by subcloning flanking sequences on either side of the selection marker. Briefly, two sets of primers, KC186/KC187 and KC188/KC189 (table 2) were made by using the Candida albicans genome sequence available at Candida Genome Database. PCR products of 525 bp and 505 bp were amplified using genomic DNA of parental strain CAF4-2. These PCR products were cloned into pTZ57R/T vector using InsTA PCR Cloning kit as recommended by the manufacturer (Thermo Fisher Scientific, Lithuania). Subsequently, these two products were digested out from pTZ57R/T and inserted at SacI/BamHI and PstI/HindIII sites of pKA16 generating the plasmid pKA244 carrying URA3 marker for first copy deletion of CNP41 gene. Second deletion construct carrying the LEU2 marker was made by replacing URA3 with LEU2 (taken out from pKA188) gene in pKA244 resulting in the plasmid pKA594. The plasmid pKA244 was digested with SacI/HindIII to release the deletion cassette and transformed into Candida strain C86 for deleting the first copy of the CNP41 gene. Subsequently, the second copy was deleted by transforming a single copy deleted strain with the plasmid pKA594. Plasmids used in this study are listed in table 3.

Zoom In Zoom Out Reset image size

Deletion of the CNP41 gene was confirmed by PCR with two pairs of primers for checking 5' and 3' junctions. Double deletions were verified with internal primers and the primers used for this purpose are listed in table 2. PCR products of 5' and 3' junctions were also digested with restriction enzymes to ensure that there are no non-specific amplifications.

Nanoparticles were synthesized using biosynthesis approach and microwave assisted technique using wild-type C. albicans strain C86. Procedure for nanoparticles biosynthesis has been briefly described herein. The Candida strain C86 stored in −80 °C ultra-freezer was streaked on YPD plate supplemented with uridine (50 μg ml⁻¹) and incubated at 30 °C for 12–16 h to get barely visible young colonies. The cells were then inoculated into a 100 ml YPD liquid supplemented with uridine (50 μg ml⁻¹). Cells were incubated at 30 °C in shaking incubator at 110 rpm for 16–18 h. The cells were filtered using Whatman grade 01 filter paper [28]. 100 ml silver nitrate solution was prepared using MilliQ water with its concentration (0.1 M). The resultant 50 ml of cell filtrate was taken and mixed with silver nitrate solution in 1:1 ratio [29]. The mixture was then heated at 600 W for 5 min till the mixture reduces Ag⁺ to Ag⁰ by changing its colour from pale yellow to brown [29].

The solution of prepared nanoparticles was subjected to double beam UV spectrophotometer (Systronics 2202, India) for primary confirmation of synthesis of AgNPs. The silver nanoparticles sample was tested along with control microbial suspension. As silver nanoparticles' range of wavelength falls under 400–480 nm, the range was set at 200–800 nm. Furthermore, the synthesised AgNPs were centrifuged to obtain pellets and then characterized by FTIR (JASCO V 600, Japan) for observing the functional groups. EDX and FESEM (Carl Zeiss sigma, Germany) techniques were incorporated to view size and shape of silver nanoparticles.

Disc diffusion test was performed to evaluate the antifungal activity as described [30]. Sterile 6 mm disks were purchased from Himedia, India. 20 μl of silver nanoparticles was pipetted onto the sterile disk. Standard disks of fluconazole (10 μg, Himedia) was used as positive control and combination of fluconazole with AgNPs was impregnated on the disks for this study. SD plates containing Candida cells and disk were incubated at 30 °C for 24–48 h until a clear zone of inhibition was formed. The diameter of these zones was measured. The protocol was followed as described [30]. Each test was conducted in triplicates to ensure reproducibility.

The increase in fold area was assessed by calculating the mean surface area of the zone of inhibition of antifungal activity of fluconazole alone and fluconazole along with AgNPs. The percentage fold increase in area of tested antifungal activity was calculated from equation (1):

$$\begin{eqnarray} &&\% \,fold\,increase\,in\,area\,of\,tested\,antifungal\,activity=\displaystyle \frac{B-A}{A}\,* \,100\end{eqnarray} \tag{ 1 }$$

where, A is the zone of inhibition of tested antifungal alone and B is the zone of inhibition of tested antifungal along with synthesized silver nanoparticle [31].

The Candida albicans strain C86 was transformed with the plasmid pKA244 by digesting with SacI/HindIII and ura⁺ transformants were obtained on plate lacking uridine (ura^- plate). The ura⁺ transformants were re-streaked on the ura^- plate to remove any false transformants. Transformants were independently processed for making genomic DNA for PCR verification of CNP41 gene deletion. PCR verification of the junctions was done as shown in figure 3. Both 5' and 3' junctions were verified by primers KC16/KC192 and KC17/KC193 respectively. The expected sizes of amplified products for 5' and 3' junction verification would be 811 bp and 901 bp, respectively. The obtained PCR products were exactly matching with the expected sizes (see figure 4(a). Further confirmation comes from the digestion of these PCR products with diagnostic restriction enzymes producing the fragments of expected size (data not shown). Approximately 15 ura⁺ transformants were screened by this process and 3 right candidates were obtained for first copy deletion of CNP41 gene. Henceforth, we refer orf19.3120 as CNP41 ( Candida Nanoparticle 41). The strain carrying the first copy deletion was designated as C386.

Zoom In Zoom Out Reset image size

Zoom In Zoom Out Reset image size

For the deletion of the second copy of the CNP41 gene, the strain C386 was transformed with the plasmid pKA594 and leu⁺ transformants were obtained on the SD plate lacking leucine. The transformants were processed for genomic DNA preparation and subsequently PCR was done to screen the right candidates. The primers KC195/KC192 and KC206/KC193 were used for verifying 5' and 3' junctions. Expected size of the PCR products are 811 bp and 901 bp, respectively. The sizes of the PCR products obtained are matching with the expected sizes (see figure 4(b)). PCR products were further digested with diagnostic restriction enzymes to ensure that they are not non-specific bands (data not shown). Approximately 40 leu⁺ transformants were screened and 8 right candidates were obtained. Deletion of CNP41 gene was further confirmed by designing a pair of internal deletion primers KC398/KC399 which would fail to amplify any product in the double copy deleted strain whereas parental strain would produce a band of 1035 bp (see figure 5). Thus, the CNP41 gene was successfully deleted, generating the strain C403 (cnp41Δ/cnp41Δ).

Zoom In Zoom Out Reset image size

Biosynthesis of silver nanoparticles using C86 strain of C. albicans was done by microwave assisted technique. The primary confirmation of the synthesised AgNPs was authenticated as the solution colour changed from pale yellow to brownish (see figure 6). Although some studies hypothesised that silver ions require NDPH dependent nitrate reductase enzyme for the reduction to AgNPs [28, 32], the exact mechanism of formation of AgNPs remains unanswered. One of the possible explanations for this study involving C. albicans is that the fungal cells secrete NDPH dependent nitrate reductase enzyme in their extracellular environment [29, 33].

Zoom In Zoom Out Reset image size

3.2.1. Double beam UV spectrophotometer

Optical measurements for the primary detection of silver nanoparticles was done using UV-Visible spectrophotometer (Systronics 2202, India) and the range of wavelength was set between 200–800 nm. As depicted in figure 7(a), the maximum absorbance peak observed at wavelength 446 nm was within the AgNPs peak range [30]. This is in accordance with several studies that reported the highest absorbance peak between 400–480 nm [28, 29].

Zoom In Zoom Out Reset image size

3.2.2. FTIR studies

3.2.3. FESEM and EDX analysis

The antifungal activity of AgNPs was carried out by incorporating antifungal agent fluconazole as it shows fungistatic activity against most of the candida strains and helps in curing fungal infections [37]. Moreover, fluconazole belongs to azole class of antifungals and is more preferred due to its broad spectrum activity, high efficacy and low toxicity [6]. The zone of inhibition of AgNPs was studied against Candida strain C403 having both the copies of CNP41 gene deleted. The wild-type strain C86 has been used as a control. As seen in figure 8, the C86 strain of C. albicans showed no zone on addition of AgNPs whereas the C403 strain showed a 10 mm zone around the 6 mm disk containing AgNPs. This finding is comparable with the works published on antifungal action on AgNPs by using ciprofloxacin [38], erythromycin [28] and fluconazole [35, 36, 38].

Zoom In Zoom Out Reset image size

It has been shown earlier that metal and metal oxide nanoparticles have always stood apart for being an effective entities as antifungal agents [28, 29, 31]. Particularly, silver nanoparticles of triangle shaped and 75 nm sized were demonstrated effectively for presenting antifungal activity with Erythromycin against penicillium spp. [28], whereas spherical shaped silver nanoparticles of size 30–45 nm along with Erythromycin exhibited three-fold antifungal activity against Fuzarium Oxysporum [29]. Additionally, copper oxide nanoparticles of size 7 nm along with fluconazole were proven as effective antifungal agents against C. albicans [39]. These results are comparable with the current antifungal study wherein spherical biosynthesized silver nanoparticles of size 30–70 nm were tested positively against Candida albicans.

An enhanced microbial activity was seen as a promising result of having fluconazole antifungal agent with the synthesised AgNPs and supported by the works published by Balaji et al and Gajbhiye et al [36, 38]. Table 4 illustrates the increase in fold area activity. It was further observed that C403 strain had an increase in fold area by 10.3% when compared to the wild-type strain C86 with its fold area being 7.4%. This increase in the fold area can be attributed to the synergetic effect of the bonding reaction between fluconazole and AgNPs. Interestingly, AgNPs did not have any effect on wild-type C86 strain with its genes intact and the presence of AgNPs were insufficient to kill the strain. However, AgNPs had shown antifungal property on C403 strain having both the copies of CNP41 gene deleted. Thus, this study strongly suggests that the CNP41 gene could play a vital role in drug resistance in C. albicans.